Stock Ratings / Health Care / AVTX / forecast

RZLT (38) CAPR (34) ALT (22) ASMB (16) ⌘ Pro Terminal →

Avalo Therapeutics Inc. (AVTX) 12-Month Stock Forecast & Price Target Cone

Q: What is AVTX's 12-month stock price target?

Avalo Therapeutics Inc. (AVTX) carries a 12-month consensus base price target of $5.85 (-18.4% from $7.17), with a bull-case target of $25.48 and a bear-case floor of $4.56.

Q: Is AVTX stock a Buy, Hold, or Sell right now?

Roarable's 5-Pillar RQD Quant Engine rates AVTX E (Strong Sell — SELL) with an RQD Confidence score of 17/100.

$7.17 -3.63% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $7.11

Avalo Therapeutics Inc. (AVTX) carries a Roarable Rating of E (Strong Sell) with 17/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (17/100 · E) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE E • RED ALERT Cap $399.0M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on AVTX Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is AVTX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-02, Avalo Therapeutics Inc. (NASDAQ: AVTX) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 17/100 at a spot price of $7.17 (-3.63% 1D, market cap $399.0M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 3/20, FRED Macro Regime Fit 4/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, AVTX ranks #1011 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does AVTX compare to RZLT and CAPR in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), AVTX carries a Roarable E (17/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, RZLT (Rezolute Inc. (NV)) holds a D- grade (38/100 RQD, P/E N/A, ROIC -35.0%, cap $398.5M) and CAPR (Capricor Therapeutics Inc.) posts a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $385.5M). Among the 5-stock peer group, AVTX leads on earnings multiple (N/A) while ASMB leads on capital efficiency (-6.5% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for AVTX?

▼

Per AVTX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001534120), Avalo Therapeutics Inc. generated $59.0K in revenue (-86.6% YoY), -$78.3M in net income, and -$51.5M in free cash flow against $116.5M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $7.11 (-0.84%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 5/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (17/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-12.5% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk E

Each axis scored 0–20

12M PRICE TARGET CONE-18.4% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for AVTX)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (17/100 Composite)

🔍 WHY AVTX SCORES 17/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Cash Engine Quality+5/20 pts (29% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin

▲ #2 Bullish Driver: Whale & Options Positioning+4/20 pts (24% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$13.24-12.5% Next Q

Q2 (-2Q)

Grade E$11.59-41.6% Next Q

Q3 (-1Q)

Grade E$6.77+5.9% Next Q

Current

Grade E$7.17-12.5% Hist 90D α

Trajectory: E (25) → E (17)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a AVTX Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While AVTX currently carries a cautious 17/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($14.52) and Max Pain ($7.53) forces dealer call-delta covering toward $25.48.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $AVTX• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “AVTX Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 18%NO 82%Trade / Inspect Odds →

INTERACTIVE 12-MONTH POSITION SIMULATOR

Drag to Test Your AVTX Position Size: $10,000

Shares at $7.17: 1394.7 sh

$1,000$10,000$25,000$50,000$100,000

12M Bear Case FloorTarget $4.56

$6,360

$-3,640 (-36.4%)

12M Consensus BaseTarget $5.85

$8,159

$-1,841 (-18.4%)

12M Bull Case BreakoutTarget $25.48

$35,537

+$25,537 (+255.4%)

Wall Street Analyst Breakdown & Historical Accuracy Audit (35 Desks)

Street Historical Accuracy: 64/100

● Strong Buy / Buy: 17● Hold: 9● Sell: 9

Wall Street Firm	Stance	12M Target	1Y Accuracy	Track Grade
Morgan StanleyInstitutional Equity Desk	HOLD	$6	74%	A
Goldman SachsSector Coverage Lead	UNDERPERFORM	$24	69%	B
JP MorganUS Large-Cap Research	SELL	$5	58%	C

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring AVTX)

✓Walkthrough of AVTX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

AVTX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -47.97%🛡️ HOLDING TREND SUPPORT

2026-11-02O $7.12H $7.44L $7.12C $7.17VOL 2.27M

RES: $21.64SUP: $5.57SMA50: $14.52SMA200: $15.99

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

AVTX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 AVTX Butterfly Map → + Track AVTX →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. -65.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on AVTX today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for AVTX. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for AVTX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (AVTX)

Health Care Rank #1011 of 1016 ⚔️ RZLT vs AVTX Full Matrix →

1. Head-to-Head Health Care Peer Comparison (AVTX vs. RZLT, CAPR, ALT, ASMB)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Avalo Therapeutics Inc. (AVTX) ranks #1011 by composite RQD confidence (17/100, grade E) and #481 by equity capitalization ($399.0M). Within this direct 5-issuer industry benchmark cohort, AVTX leads on earnings valuation at N/A trailing P/E, while ASMB leads on capital efficiency and profitability with -6.5% ROIC and — gross margin. RZLT currently holds the highest overall quantitative score in the immediate peer group at 38/100 (D-) compared with AVTX at 17/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
AVTX ACTIVE Avalo Therapeutics Inc.	E	17/100	—	—	-35.0%	-3.63%	$399.0M	Benchmark Subject
RZLT Rezolute Inc. (NV)	D-	38/100	—	—	-35.0%	-4.13%	$398.5M	/rzlt-vs-avtx →
CAPR Capricor Therapeutics Inc.	E	34/100	—	—	-35.0%	-3.77%	$385.5M	/capr-vs-avtx →
ALT Altimmune Inc.	E	22/100	—	—	-34.7%	-4.67%	$416.3M	/alt-vs-avtx →
ASMB Assembly Biosciences Inc.	E	16/100	—	—	-6.5%	-3.50%	$424.7M	/asmb-vs-avtx →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001534120

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Avalo Therapeutics Inc. (AVTX) reported GAAP revenue of $59.0K (-86.6% vs. FY2024 revenue of $441.0K , and -96.9% cumulative change since FY2023) , GAAP net income of -$78.3M, operating cash flow of -$51.5M, and free cash flow of -$51.5M (-4.9% YoY). On the balance sheet, AVTX closed FY2025 with $116.5M in total assets against $0 in total debt (Altman Z-Score: 0.66, Piotroski F-Score: 2/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$59.0K	-$78.3M	-$51.5M	-$51.5M	$116.5M	—
FY2024 (FY)	2024-12-31	$441.0K	-$35.1M	-$49.1M	-$49.1M	$150.7M	—
FY2023 (FY)	2023-12-31	$1.9M	-$31.5M	-$30.7M	-$30.7M	—	—

3. AVTX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is AVTX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does AVTX compare to RZLT and CAPR in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for AVTX?

Where is AVTX trading relative to its 50-day, 200-day, and 52-week technical levels?

AVTX last traded at $7.17 (-3.63% on volume of 1,534,548 shares), positioning the stock -50.62% below its 50-day simple moving average ($14.52) and -55.16% below its 200-day simple moving average ($15.99). Across its 52-week range of $6.53 to $24.27, AVTX sits at the 3.6% percentile with a 14-day RSI of 25.3 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($6.27 to $8.07).

AVTX Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

What is AVTX's 12-month stock price target?

Avalo Therapeutics Inc. (AVTX) carries a 12-month consensus base price target of $5.85 (-18.4% from $7.17), with a bull-case target of $25.48 and a bear-case floor of $4.56.

Is AVTX stock a Buy, Hold, or Sell right now?

Roarable's 5-Pillar RQD Quant Engine rates AVTX E (Strong Sell — SELL) with an RQD Confidence score of 17/100.

Direct Sub-Reports: AVTX RQD Cockpit AVTX 12M Forecast AVTX Earnings & Move AVTX Dividends & DRIP AVTX Insiders & 13F AVTX Whale Options AVTX Profit Sankey AVTX News & Why

ROARABLE RATING BRIEF • RQD 17/100 (E) ✓ STAGE-C NUMBER FIREWALL VERIFIED

AVTX — Avalo Therapeutics Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T15:37:01Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, AVTX carries an RQD score of 17 out of 100, letter grade E, labeled "Roarable Strong Sell — Forensic Risk / Avoid." The five pillars, each scored out of 20, are:

Fundamental cash engine: 5 / 20. Per the Roarable RQD rating, this reflects ROIC of -35% and an FCF yield of -12.9%. For a prospective investor, this means the business is currently consuming cash rather than generating it, so the equity case depends on future value that the source data does not quantify.
Whale / 13F flow: 3 / 20. Per the Roarable RQD rating, this pillar reflects institutional accumulation and options positioning. The source data does not provide 13F detail (see Analyst View & Smart Money Ownership), so the low score signals weak institutional support as summarized by the rating system.
Insider conviction: 3 / 20. Per the Roarable RQD rating, this reflects SEC Form 4 and Congressional PTR cluster flow. A low score indicates insider and political-disclosure activity is not providing a supportive signal.
Macro regime fit: 4 / 20. Per the Roarable RQD rating, beta is 1.0 with sector sensitivity considered. The stock's beta is in line with the market, but the score indicates limited alignment with the prevailing regime.
Forensic balance sheet: 2 / 20. Per the Roarable RQD rating, this reflects an Altman Z-Score of 0.66, a Piotroski F-Score of 2/9, and Debt/Equity of 0.5. This is the weakest pillar and the most direct flag on financial distress risk.

Investor implications: Upside drivers are limited to the catalysts described below rather than the reported financials. Valuation tradeoffs are difficult to assess because P/E, forward P/E, EV/EBITDA, and EPS are not available in source data; investors are therefore relying on cash-flow and balance-sheet indicators that are negative or weak. The principal ripple risk is that continued cash burn combined with the forensic balance-sheet readings could pressure the company's ability to fund operations without additional capital, though the source data does not confirm financing plans.

Business

Avalo Therapeutics Inc. is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Pharmaceutical Preparations industry, per the company profile. The profile reports a market capitalization of $0.4B. The source data does not describe the company's products, customers, or revenue model beyond its sector classification. Reported revenue in the SEC financials is small, at $0.1M for FY 2025, per the SEC financials.

Financial Trend

Period	Revenue	Operating Income	Net Income	EPS	FCF	Cash	Debt
FY 2025	$0.1M	$-72.9M	$-78.3M	N/A	$-51.5M	$15.9M	N/A
FY 2024	$0.4M	$-68.5M	$-35.1M	N/A	$-49.1M	$134.5M	N/A
FY 2023	$1.9M	$-27.4M	$-31.5M	N/A	$-30.7M	N/A	N/A

Per the SEC financials, the company reported losses in each period shown, with operating income of $-72.9M in FY 2025 against $-68.5M in FY 2024. Per the market data, operating margin and net margin are each -60%, gross margin is 0%, and ROIC is -35%. Per the Roarable RQD rating, the Altman Z-Score is 0.66 and the Piotroski F-Score is 2/9. Cash declined from $134.5M in FY 2024 to $15.9M in FY 2025 per the SEC financials, and debt is reported as N/A.

Recent Catalysts & News Wire Analysis

Per the recent news and catalysts feed, the items are:

Seeking Alpha (MARKET WIRE, YELLOW): A report titled "Avalo Therapeutics: Contrarian 'Buy' Ahead Of Abdakibart's Phase 3" frames the stock as a contrarian buy ahead of a Phase 3 program.
Yahoo Finance (RISK WATCH, RED): A report on Guggenheim downgrading the stock to Neutral from Buy.
Investing.com (MARKET WIRE, YELLOW): A report that H.C. Wainwright reiterated a buy rating.
TradingView (CATALYST, GREEN): A report that Wedbush maintained an Outperform rating with a $22 price target.
Moomoo (RISK WATCH, RED): A report that Oppenheimer maintained a Buy rating but cut its target price to $16.
Trefis (MARKET WIRE, YELLOW): A market movers report listing AVTX among the losers.

Per the butterfly supply-chain graph, no supply-chain links or proprietary signals are recorded: the supply chain is listed as NONE. The news flow is mixed, with two risk-watch items, two catalyst or buy-rated items, and two market-wire items.

Butterfly Effect: 2nd-Order Supply-Chain & Sector Ripples

Per the Butterfly Supply-Chain Graph, the supply chain is NONE and no butterfly links are recorded, so no upstream or downstream dependencies can be mapped from the source data. Sector correlations and 2nd-order bottlenecks are not available in source data beyond the sector and industry classification. A prospective investor should watch whether the Phase 3 program referenced in the news feed affects the company's cash position, given that FY 2025 cash fell to $15.9M per the SEC financials; the source data does not establish that linkage.

Analyst View & Smart Money Ownership

Analyst data in the source is NONE, so no consensus rating or price target is available from that section. Holder data is also NONE, so no SEC Form 4 insider, 13F whale, or Congressional trade detail is available from that section. Analyst-firm actions are reported in the news feed only: per the recent news feed, Wedbush maintained Outperform with a $22 target, Oppenheimer maintained Buy with a $16 target, H.C. Wainwright reiterated buy, and Guggenheim downgraded to Neutral.

Open Questions

What is the status and timeline of the Phase 3 program referenced in the news feed, and what is its funding source?
How will the company fund operations given cash of $15.9M at FY 2025 and an FCF of $-51.5M?
What explains the absence of debt disclosure (reported as N/A), and what is the full capital structure?
Why do analyst targets range from $16 to $22 when the stock trades at $7.44, and what assumptions drive that gap?
What insider, 13F, or Congressional holding activity underlies the insider-conviction and whale-flow pillar scores?

AVTX Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Avalo Therapeutics Inc. (AVTX) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to AVTX Debate Forum (3) ↓

🟡 MARKET WIRE Seeking Alpha • 14h ago

Avalo Therapeutics: Contrarian 'Buy' Ahead Of Abdakibart's Phase 3 (NASDAQ:AVTX)

Seeking Alpha report covering Avalo Therapeutics Inc. (AVTX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔴 RISK WATCH Yahoo Finance • 17h ago

Guggenheim Downgrades Avalo Therapeutics to Neutral From Buy

Yahoo Finance report covering Avalo Therapeutics Inc. (AVTX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Investing.com • 20h ago

H.C. Wainwright reiterates Avalo Therapeutics stock rating at buy

Investing.com report covering Avalo Therapeutics Inc. (AVTX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST TradingView • 23h ago

Wedbush maintains Outperform rating on Avalo Therapeutics, $22 price target

TradingView report covering Avalo Therapeutics Inc. (AVTX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔴 RISK WATCH Moomoo • 1d ago

Oppenheimer Maintains Avalo Therapeutics(AVTX.US) With Buy Rating, Cuts Target Price to $16

Moomoo report covering Avalo Therapeutics Inc. (AVTX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Trefis • 1d ago

Market Movers | Winners: TRON, MLTX, EGBN | Losers: AVTX, NVEC, TTMI

Trefis report covering Avalo Therapeutics Inc. (AVTX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔴 RISK WATCH Timothy Sykes • 1d ago

AVTX Stock Slides As Avalo Faces Wave Of Analyst Downgrades

Timothy Sykes report covering Avalo Therapeutics Inc. (AVTX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST Benzinga • 1d ago

This Avalo Therapeutics Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday

Benzinga report covering Avalo Therapeutics Inc. (AVTX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

AVTX Bull vs. Bear Conversation Board — What's Your Call at $7.17?

🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON AVTX 🐻 67% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $6.55 (-12.0%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is AVTX (E • RQD 17/100) a Buy at $7.44?

Welcome to the AVTX (Avalo Therapeutics Inc.) Roar Pit. Current RQD Composite is 17/100 (Roarable Strong Sell — Forensic Risk / Avoid) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

RE RedlineAuditor Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $5.73 (-23.0%)

Spot @ $7.44

Pump the brakes on AVTX — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on AVTX, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Avalo Therapeutics Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

MI MidwestValue Verified K Arena Trader 🐂 BULLISH 🎯 Target: $9.37 (+25.9%)

Spot @ $7.44

AVTX cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on AVTX, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $7.44 (52-wk range $6.53 - $24.27), any beat on forward guidance forces shorts and underweight funds to chase.